AEGERION PHARMACEUTICALS LIMITED
Get an alert when AEGERION PHARMACEUTICALS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£8.3m
-0.8% vs 2024
Net assets
£43m
-2.6% vs 2024
Employees
—
Average over period
Profit before tax
-£1.2m
-144.7% vs 2024
Net assets
3-year trend · vs Consumer Discretionary median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £1,968,347 | £2,288,795 | £2,533,251 | +10.7% | |
| Operating profit | -£1,562,251 | £2,583,765 | -£1,155,934 | -144.7% | |
| Profit before tax | -£1,562,251 | £2,583,765 | -£1,155,934 | -144.7% | |
| Net profit | -£1,562,251 | £2,583,765 | -£1,155,934 | -144.7% | |
| Cash | £1,118,518 | £8,357,228 | £8,287,870 | -0.8% | |
| Total assets less current liabilities | £41,818,167 | £44,401,933 | £43,245,999 | -2.6% | |
| Net assets | £41,818,167 | £44,401,933 | £43,245,999 | -2.6% | |
| Equity | £41,818,167 | £44,401,933 | £43,245,999 | -2.6% | |
| Average employees | — | — | — | — | |
| Wages | — | — | — | — | |
| Directors' remuneration | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | -79.4% | 112.9% | -45.6% | |
| Net margin | -79.4% | 112.9% | -45.6% | |
| Return on capital employed | -3.7% | 5.8% | -2.7% | |
| Gearing (liabilities / total assets) | 10.3% | 3.8% | 3.1% | |
| Current ratio | 2.60x | 9.02x | 13.04x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte Ireland LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The financial statements of the Company are prepared on a going concern basis on the basis that management have no intention of either liquidating the entity or ceasing trading, or has no realistic alternative but to do so.”
Group structure
- AEGERION PHARMACEUTICALS LIMITED · parent
- Amryt Turkey ILac Ticaret Limited Sirketi 100%
Significant events
- “During 2024, the shareholding of Amryt Pharma GmbH was sold to a fellow Chiesi affiliate and Aegerion Pharmaceuticals BV was liquidated.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 19 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| WIGGETTS, Matthew Hammond | Secretary | 2023-05-26 | — | — |
| DICKINSON, Andrew Philip | Director | 2023-05-26 | Dec 1970 | British |
| FEELY, Gerard | Director | 2024-09-26 | Jan 1982 | Irish |
| WIGGETTS, Matthew Hammond | Director | 2023-05-26 | May 1972 | British |
Show 19 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| COOK, Anne Marie | Secretary | 2012-06-21 | 2014-05-01 |
| HOGAN, Ailish | Secretary | 2019-09-24 | 2023-05-26 |
| CORPORATION SERVICE COMPANY (UK) LIMITED | Corporate Secretary | 2021-01-04 | 2023-08-01 |
| SISEC LIMITED | Corporate Secretary | 2012-06-21 | 2019-09-24 |
| ALLMOND, David | Director | 2016-07-15 | 2017-03-31 |
| BORIERO, Massimo | Director | 2013-02-21 | 2015-01-16 |
| BOURSIER, Jean-Yves Philippe | Director | 2012-06-21 | 2016-07-15 |
| CHAN, Barbara | Director | 2017-10-01 | 2019-09-24 |
| COOK, Anne Marie | Director | 2012-06-21 | 2014-05-01 |
| GLENNANE, David John | Director | 2019-09-24 | 2023-07-13 |
| HARSHBARGER, Benjamin Scott | Director | 2017-12-18 | 2019-09-24 |
| HARSHBARGER, Benjamin Scott | Director | 2014-05-01 | 2016-07-15 |
| HOGAN, Ailish | Director | 2023-05-26 | 2024-09-26 |
| KIDD, Janet Louise | Director | 2016-07-15 | 2017-12-18 |
| MCEVOY, John | Director | 2019-09-24 | 2023-05-26 |
| ROTHERA, Mark | Director | 2012-06-21 | 2013-02-21 |
| SEEBERGER, David Henrik | Director | 2016-07-15 | 2017-10-01 |
| TRIMMING, Julian William | Director | 2016-07-15 | 2017-10-01 |
| TRIMMING, Julian William | Director | 2014-05-01 | 2014-12-11 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Amryt Pharma Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-09-24 | Active |
| Novelion Therapeutics Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-11-29 | Ceased 2019-09-24 |
| Aegerion Pharmaceuticals, Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2016-11-29 |
Filing timeline
Last 20 of 96 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-10 | AA | accounts | Accounts with accounts type full | |
| 2026-07-01 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-09-29 | AA | accounts | Accounts with accounts type full | |
| 2025-09-16 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-07-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-09 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-03 | TM01 | officers | Termination director company with name termination date | |
| 2024-09-05 | AA | accounts | Accounts with accounts type full | |
| 2024-06-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-09-23 | AA | accounts | Accounts with accounts type full | |
| 2023-08-08 | TM02 | officers | Termination secretary company with name termination date | |
| 2023-07-26 | TM01 | officers | Termination director company with name termination date | |
| 2023-07-10 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-06-01 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-01 | AP03 | officers | Appoint person secretary company with name date | |
| 2023-06-01 | TM01 | officers | Termination director company with name termination date | |
| 2023-06-01 | TM02 | officers | Termination secretary company with name termination date | |
| 2023-06-01 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-01 | AP01 | officers | Appoint person director company with name date | |
| 2023-04-19 | MR04 | mortgage | Mortgage satisfy charge full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.